Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
Conditions
Interventions
VX-264
Locations
16
United States
UHealth Diabetes Research Institute
Miami, Florida, United States
University of Chicago
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Montefiore
Pittsburgh, Pennsylvania, United States
University of Wisconsin
Madison, Wisconsin, United States
Start Date
May 16, 2023
Primary Completion Date
May 29, 2026
Completion Date
May 29, 2026
Last Updated
August 11, 2025
NCT07224321
NCT06815081
NCT07051005
NCT05188027
NCT07212179
NCT02734277
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions